Cytek Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cytek Biosciences, Inc. (CTKB) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-6.02-12.152.583.0519.41
Depreciation & Amortization10.492.575.661.240.60
Deferred Income Tax-2.890.000.000.000.00
Stock Based Compensation26.8522.0516.606.590.61
Change in Working Capital7.71-7.10-39.93-8.65-7.54
Change in Accounts Receivable-5.43-7.33-19.74-12.370.33
Change in Inventory14.764.29-17.65-7.07-5.70
Change in Accounts Payable2.58-1.781.86-0.26-0.06
Change in Other Working Capital-7.19-12.20-13.801.97-4.49
Other Operating Activities-7.1921.952.841.971.89
Net Cash from Operating Activities25.385.28-12.234.6315.16
Investing Activities
Capital Expenditures-3.73-4.65-9.75-4.36-1.55
Acquisitions-0.47-45.130.00-17.000.00
Purchases of Investments-274.06-43.94-46.040.000.00
Sales/Maturities of Investments195.00-175.94-0.120.370.00
Other Investing Activities0.08-175.94-44.450.370.00
Net Cash from Investing Activities-82.97-93.89-55.91-20.99-1.55
Financing Activities
Debt Repayment-0.56-0.57-0.05-2.77-1.31
Common Stock Issued0.003.322.79215.690.17
Common Stock Repurchased-21.61-44.57-0.210.000.00
Other Financing Activities-0.55-0.42-0.21-2.770.00
Net Cash from Financing Activities-15.82-41.815.51213.56122.61
Summary
Effect of Forex Changes on Cash4.53-1.45-2.491.300.00
Net Change in Cash-73.42-131.87-65.12197.20135.63
Cash at Beginning of Period167.63299.50364.62166.120.00
Cash at End of Period98.75-170.65299.50364.620.00
Free Cash Flow21.655.28-21.980.2713.61
Supplemental Disclosures
Income Taxes Paid3.835.3110.392.862.07